Ardelyx (ARDX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.02
- Surprise
- +100.0%
- Revenue (period 2026-09-30)
- $127.7M
- Score today
- 6.3/10
Revenue source: xbrl.
Coverage in the report window
- Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial for IBSRELA in Chronic Idiopathic Constipation — fiscal.ai, 2026-11-03
- Ardelyx Q3 2026 Earnings Call Transcript — benzinga, 2026-11-03
- Ardelyx Q3 Sales $125.500M Miss $128.420M Estimate — benzinga, 2026-11-03
Where TrendMatrix's rating stands now
TrendMatrix currently rates ARDX Sell at 6.3/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's +100.0% surprise compares with a -11.6% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Product: IBSRELA
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0)
- Leverage penalty (D/E 1.9): -1.0
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.03
- Price target
- $3.28
- Stop
- $2.87
- Upside to target
- +8.3%
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
ARDX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $782.3M
- P/E (fwd)
- 10.3
- 52-week range
- $2.96–$8.40
- Off 52-week high
- 63.9%
- RSI (14)
- 41
- Volume vs avg
- 1.40×
- Score today
- 6.3/10